Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy

Condition:   Idiopathic Angioedema
Interventions:   Drug: Omalizumab;   Drug: Placebos
Sponsors:   University of Wisconsin, Madison;   Novartis Pharmaceuticals
Not yet recruiting – verified November 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days

Leave a Reply

Your email address will not be published. Required fields are marked *